In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus

doi:10.1016/j.jmii.2016.04.009

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/32207

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32207

Title:	In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus
Authors:	Tang, Hung-Jen Chen, Chi-Chung Lai, Chih-Cheng Zhang, Chun-Cheng Weng, Tzu-Chieh Chiu, Yu-Hsin Toh, Han-Siong Chiang, Shyh-Ren Yu, Wen-Liang Ko, Wen-Chien Chuang, Yin-Ching
Contributors:	Chi Mei Med Ctr, Dept Med Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Chi Mei Med Ctr, Dept Med Res Chi Mei Med Ctr, Dept Intens Care Med Chi Mei Med Ctr, Dept Med Natl Cheng Kung Univ, Med Coll & Hosp, Dept Med
Keywords:	killing effects tigecycline Vibrio vulnificus
Date:	2018-02
Issue Date:	2019-11-15 15:45:12 (UTC+8)
Publisher:	ELSEVIER TAIWAN
Abstract:	Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the timeekill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 mu g/mL, 0.03-0.06 mu g/mL, and 0.03-0.06 mu g/mL, respectively. In time ekilling studies, at the concentration of 1 x MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 x MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 x MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 x 10(5) CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 x 10(6) CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections. Copyright (C) 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
???metadata.dc.relation.uri???:	http://dx.doi.org/10.1016/j.jmii.2016.04.009
Relation:	Journal of Microbiology Immunology and Infection, v.51, n.1, pp.76-81
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
10.1016-j.jmii.2016.04.009.pdf		377Kb	Adobe PDF	337	View/Open
index.html		0Kb	HTML	1060	View/Open

Loading...